< back to search

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Baeten [II], Dominique   •   Sieper, Joachim   •   Braun, Jurgen   •   Baraliakos, Xenofon   •   Dougados, Maxime   •   Emery, Paul   •   Deodhar, Atul   •   Porter, Brian   •   Martin, Ruvie   •   Andersson, Mats   •   Mpofu, Shephard   •   Richards, Hanno B

published in: The New England journal of medicine



endpoint

Sekukinumab has (optional: compared with placebo) proved to be better.
general condition better


basics

diagnosis:
ankylosing spondylitis

localization:
not specified

method:
conservative therapy → injection
conservative therapy → injection therapy

publication details

10.1056/NEJMoa1505066
26699169
2015
randomized controlled trial
yes
prospective
1+

▼
▲